TH-OR024
Randomized, Double-Blinded,Active-Controlled (Darbepoetin Alfa), Phase 3 Study of Vadadustat in Chronic Kidney Disease Patients With Anemia on Hemodialysis in Japan
Masaomi Nangaku1 | 1The University of Tokyo |
Kazuoki Kondo2 | School of Medicine, |
Tokyo, Japan | |
Kiichiro Ueta2 | 2Mitsubishi Tanabe |
Pharma Corporation, | |
Yoshimasa Kokado2 | Tokyo, Japan |
Genki Kaneko2 | 3Gunma University, |
Graduate School of | |
Hiroki Matsuda2 | Medicine, Maebashi, |
Gunma, Japan | |
Yutaka Kawaguchi2 | |
Yasuhiro Komatsu3 |
American Society of Nephrology (ASN); Washington, DC, USA; November 5-10, 2019
Disclosures
Funding
- This study was funded by Mitsubishi Tanabe Pharma Corporation.
Potential conflicts of interest
- Masaomi Nangaku has received honoraria, advisory fees, or research funding from Akebia, Alexion, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, GSK, JT, Kyowa Kirin, Mitsubishi Tanabe, Ono, Takeda, and Torii.
- Genki Kaneko, Yutaka Kawaguchi, Yoshimasa Kokado, Kazuoki Kondo, Hiroki Matsuda, and Kiichiro Ueta are employees of Mitsubishi Tanabe Pharma Corporation.
- Yasuhiro Komatsu has received personal fees from Baxter, Chugai, and Kyowa Kirin.
Acknowledgments
- The authors thank the study team and staff for the conduct of this study, their colleagues at Akebia Therapeutics Inc. for editorial input and support with the development of this presentation, and the patient volunteers for participating in the study. The authors would also like to thank Serina Stretton, PhD, CMPP, and Yuriko Kikuchi-Rech, PhD, of ProScribe - Envision Pharma Group for medical writing assistance funded by Mitsubishi Tanabe Pharma Corporation.
2
Introduction
Background
- Vadadustat (VDT) is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) under development for the treatment of anemia in patients with CKD
- Phase 2 trials for the treatment of anemia in patients with NDD-CKD and HD-CKD have been conducted1-4
- This study in Japan is the first double-blind,active-controlled phase 3 study (NCT03439137) of VDT for treatment of anemia in patients with HD-CKD for up to 52 weeks
Objectives
- The primary endpoint was to demonstrate noninferiority of VDT in average Hb at weeks 20 and 24 compared with DA for treatment of anemia in patients with HD-CKD who were receiving ESAs
- Here, we present the results for the prespecified primary analysis up to week 24 and recently available data for durability of efficacy and long-term safety up to week 52
DA, darbepoetin alfa; Hb, hemoglobin; HD, hemodialysis-dependent; NDD, nondialysis-dependent; VDT, vadadustat. | 3 |
1. Pergola PE, et al. Kidney Int. 2016;90(5):1115-22; 2. Martin ER, et al. Am J Nephrol. 2017;45:380-88; 3. Haase VH, et al. Nephrol Dial Transplant. 2019;34(1):90-99; |
4. Nangaku M, et al. ASN Kidney Week, San Diego, CA, USA; October 23-28, 2018.
Study Design
Multicenter, randomized, double-blinded,active-controlled,double-dummy, phase 3, conducted in Japan
- Target Hb: 10.0-12.0 g/dL
- Main dose adjustment algorithm: adjusted VDT and DA to maintain target Hb
- Dose increase: Hb <10.0 g/dL; dose reduction: Hb >11.5 g/dL
- Interval for dose increase: ≥4 weeks for VDT and ≥2 weeks for DA
- Iron supplementation: administered to maintain serum ferritin ≥100 ng/mL or TSAT ≥20%
Screening | Treatment period | Follow-up | |||||||
(up to | period | ||||||||
(52 weeks) | |||||||||
6 weeks) | (2 weeks) | ||||||||
Period I (24 weeks) | Period II (28 weeks) | ||||||||
Randomization ratio)(1:1 | VDT | ||||||||
Starting dose: 300 mg QD | |||||||||
N = 162 | Maintenance dose: 150-600mg QD | ||||||||
DA | |||||||||
Starting dose: Determined according to prior ESA dose | |||||||||
N = 161 | |||||||||
Maintenance dose: 5-180 µg QW, Q2W, or Q4W | |||||||||
Q2W, once every 2 weeks; Q4W, once every 4 weeks; QD, once daily; QW, once every week; TSAT, transferrin saturation. | 4 |
Key Inclusion Criteria
- Age: ≥20 years
- Hemodialysis status: hemodialysis or hemodiafiltration 3 times/week for ≥12 weeks before screening
- ESA use: had used same ESA for ≥8 weeks before screening
- Epoetin alfa, epoetin beta, or epoetin kappa (≤9000 IU/week)
- Darbepoetin alfa (≤60 µg/week)
- Epoetin beta pegol (≤250 µg/4 weeks)
- Baseline Hb level: ≥9.5 to ≤12.0 g/dL
- Iron parameters: serum ferritin ≥100 ng/mL or TSAT ≥20%
5
Statistical Analysis
Primary Endpoint (FAS)
- Noninferiority: VDT was considered noninferior to DA if the 95% CI lower limit for the difference between VDT and DA in the LSMean of the average Hb at weeks 20 and 24 was more than or equal to the predefined noninferiority margin of -0.75 g/dL
- Difference in LSMean: MMRM with an unstructured covariance matrix within patients
Sample Size
- Planned sample size: 300 enrolled and randomized patients (VDT: 150 patients; DA: 150 patients)
- This sample size was calculated to give 95% power for noninferioity with a two-sided alpha of 0.05 based on the following assumptions: the average Hb at weeks 20 and 24 for DA = 11.0 g/dL, difference in average Hb between VDT and DA = 0, with a noninferiority margin of -0.75 g/dL and standard deviation of 1.73 g/dL
CI, confidence interval; FAS, full analysis set; LS, Least Squares; MMRM, mixed-model repeated measures. | 6 |
FAS: patients with ≥1 study drug dose and ≥1 efficacy measurement after randomization; SAF: safety analysis set; all patients with ≥1 dose of study drug. | |
Patient Disposition
Randomized (VDT:DA = 1:1)
N = 323
VDT
N = 162
Discontinued, N = 26
- Withdrew consent, n = 10
- AEs, n = 10
- Received rescue therapy, n = 2
- Hyperviscosity syndrome, difficult to control Hb within target range, n = 4
DA
N = 161
Discontinued, N = 9
- Withdrew consent, n = 2
- AEs, n = 4
- Received rescue therapy, n = 1
- Other, investigator discretion, n = 2
Completed treatment period I | Completed treatment period I |
N = 136 | N = 152 |
AE, adverse event. | 7 |
Patient Characteristics at Baseline (FAS)
VDT | DA | |||
Characteristic | N = 162 | N = 161 | ||
Sex (male), n (%) | 104 (64.2) | 109 (67.7) | ||
Age (years) | 66.0 ± 11.3 | 64.9 ± 11.7 | ||
Body weight (kg) (dry weight) | 58.1 ± 11.9 | 58.8 ± 13.8 | ||
BMI (kg/m2) | 22.4 ± 3.4 | 22.4 ± 4.5 | ||
Hb (g/dL) | 10.73 ± | 0.7 | 10.73 ± 0.7 | |
Duration of dialysis (years) | 7.4 ± 6.7 | 7.6 ± 7.6 | ||
Serum ferritin (ng/mL) | 144.5 ± 139.6 | 140.0 ± 95.3 | ||
TSAT (%) | 28.6 ± 10.6 | 26.9 ± 9.4 | ||
Prior ESA | n (%) | Weekly dose | n (%) | Weekly dose |
Epoetin (IU) | 49 (30.2) | 3704 ± 2118 | 53 (32.9) | 4783 ± 3183 |
Darbepoetin alfa (µg) | 97 (59.9) | 17.2 ± 12.2 | 90 (55.9) | 18.7 ± 14.1 |
Epoetin beta pegol (µg) | 16 (9.9) | 18.8 ± 12.1 | 18 (11.2) | 22.9 ± 17.4 |
Comorbidities, n (%) | ||||
Hypertension | 152 (93.8) | 147 (91.3) | ||
Diabetes mellitus | 35 (21.6) | 49 (30.4) | ||
Dyslipidemia | 59 (36.4) | 79 (49.1) | ||
Data are mean ± SD unless otherwise noted.
8
Primary Endpoint (FAS)
- VDT demonstrated noninferiority to DA as measured by average Hb at weeks 20 and 24
- The 95% CIs for both the VDT and DA groups were within the target Hb range of 10.0-12.0 g/dL
- The 95% CI lower limit of the difference between groups (VDT-DA) was above the predefined noninferiority margin of -0.75 g/dL, confirming the noninferiority of VDT to DA
LSMean of the average Hb at weeks 20 and 24 and the difference
between VDT and DA
Average Hb, weeks 20 and 24 | |||
Treatment group | N | LSMean* | 95% CI |
VDT | 160 | 10.61 | 10.45, 10.76 |
DA | 160 | 10.65 | 10.50, 10.80 |
Difference (VDT-DA) | -0.05 | -0.26, 0.17 | |
*This MMRM model included treatment group, visits, interaction of treatment group and visits as fixed effects, baseline values as covariate effects, and subject as a random effect (covariance matrix: unstructured).
9
Mean Hb Over Time, 24 Weeks (FAS)
13 | |||||||||||||
(g/dL) | 12 | ||||||||||||
11 | |||||||||||||
Hb | 10 | ||||||||||||
Mean | VDT | ||||||||||||
9 | DA | ||||||||||||
8 | Patients, n: | ||||||||||||
162 | 160 | 157 | 155 | 150 | 150 | 147 | 144 | 140 | 138 | 161 | VDT | ||
7 | 161 | 160 | 159 | 159 | 158 | 157 | 157 | 156 | 154 | 152 | 161 | DA | |
BL | 2 | 4 | 6 | 8 | 10 | 12 | 16 | 20 | 24 | LOCF | |||
Weeks |
Data are mean (95% CI). | 10 |
BL, baseline; LOCF, last observation carried forward. | |
Mean Hb Over Time, 52 Weeks (FAS)
13 | ||||||||||||||||||||
12 | ||||||||||||||||||||
(g/dL) | 11 | |||||||||||||||||||
Hb | 10 | |||||||||||||||||||
Mean | VDT | |||||||||||||||||||
9 | DA | |||||||||||||||||||
8 | Patients, n: | |||||||||||||||||||
162 | 160 157 | 155 150 150 | 147 | 144 | 140 | 138 | 132 | 131 | 126 | 122 | 118 | 118 | 115 | 161 | VDT | |||||
7 | 161 160 159 | 159 158 157 | 157 | 156 | 154 | 152 | 150 | 146 | 142 | 141 | 139 | 133 | 133 | 161 | DA | |||||
BL | 2 | 4 | 6 | 8 | 10 | 12 | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 44 | 48 | 52 | LOCF | |||
Weeks |
Data are mean (95% CI). | 11 |
BL, baseline; LOCF, last observation carried forward. | |
Maintenance Rate of Target Hb Level (FAS)
Proportion of patients within the target Hb range | |||||||||||||||||||||||
100 | VDT | DA | |||||||||||||||||||||
(%) | |||||||||||||||||||||||
Above: ≥12.0 g/dL | |||||||||||||||||||||||
patients | 80 | ||||||||||||||||||||||
60 | Within: ≥10.0 to | ||||||||||||||||||||||
<12.0 g/dL | |||||||||||||||||||||||
of | |||||||||||||||||||||||
Proportion | 40 | Below: <10.0 g/dL | |||||||||||||||||||||
20 | |||||||||||||||||||||||
0 | BL | 2 | 4 | 6 | 8 | 10 | 12 | 16 | 20 | 24 | BL | 2 | 4 | 6 | 8 | 10 | 12 | 16 | 20 | 24 | |||
Weeks | Weeks | ||||||||||||||||||||||
600 | Mean daily dose of VDT | 40 | Mean weekly dose of DA | ||||||||||||||||||||
(mg)VDT | 450 | 30 | |||||||||||||||||||||
(DAμg) | |||||||||||||||||||||||
20 | |||||||||||||||||||||||
300 | 10 | ||||||||||||||||||||||
150 | 0 | BL -2 | 2-4 | 4-6 | 6-8 | 8-10 10 -12 | 12 -16 | 16 -20 | 20 -24 | ||||||||||||||
BL -2 | 2-4 | 4-6 | 6-8 | 8-10 10 -12 | 12 -16 | 16 -20 20 -24 | |||||||||||||||||
Weeks | Weeks |
Data for average dose are mean (95% CI). | 12 |
BL, baseline. | |
Mean Hb Over 24 Weeks in VDT-Treated Subgroups Stratified by Prior ESA or Baseline Hb (FAS)
Mean Hb by prior ESA therapy | Mean Hb by baseline Hb |
13 | Epoetin | DA | Epoetin beta pegol | 13 | |||||||||||
12 | 12 | ||||||||||||||
(g/dL) | 11 | (g/dL) | 11 | ||||||||||||
10 | |||||||||||||||
Hb | Hb | ||||||||||||||
10 | |||||||||||||||
9 | |||||||||||||||
Mean | Mean | ||||||||||||||
8 | 9 | ||||||||||||||
Patients, n: | |||||||||||||||
7 | 49 | 49 | 48 | 47 | 47 | 47 | 46 | 46 | 46 | 46 | 49 | Epoetin | 8 | ||
97 | 95 | 93 | 92 | 87 | 87 | 85 | 84 | 81 | 79 | 96 | DA | ||||
6 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 14 | 13 | 13 | 16 | EBP | 7 | ||
BL | 2 | 4 | 6 | 8 | 10 | 12 | 16 | 20 | 24 | LOCF | |||||
Weeks |
Baseline Hb (g/dL): | <10.4 | ≥10.4 to <11 | ≥11 | ||||||||
Patients, n: | |||||||||||
57 | 55 | 53 | 52 | 51 | 50 | 48 | 48 | 47 | 45 | 56 | <10.4 |
44 | 44 | 43 | 43 | 43 | 43 | 43 | 43 | 42 | 42 | 44 | ≥10.4 to <11 |
61 | 61 | 61 | 60 | 56 | 57 | 56 | 53 | 51 | 51 | 61 | ≥11 |
BL | 2 | 4 | 6 | 8 | 10 | 12 | 16 | 20 | 24 | LOCF | |
Weeks |
Data are mean (95% CI). | 13 |
BL, baseline; LOCF, last observation carried forward. | |
Iron-Related Parameters (FAS)
210 | Serum ferritin (ng/mL) | 40 | TSAT (%) | 400 | TIBC (μg/dL) | |||||||||||||||||||||||||||||||
35 | 360 | |||||||||||||||||||||||||||||||||||
180 | ||||||||||||||||||||||||||||||||||||
320
150 | 30 | ** | |||||||||||||||||||||||||||||
280 | |||||||||||||||||||||||||||||||
120 | 25 | 240 | |||||||||||||||||||||||||||||
90 | 20 | 200 | |||||||||||||||||||||||||||||
BL | 2 | 4 | 6 | 8 | 10 | 12 | 16 | 20 | 24 | LOCF | BL | 2 | 4 | 6 | 8 | 10 | 12 | 16 | 20 | 24 | LOCF | BL | 2 | 4 | 6 | 8 | 10 12 | 16 | 20 | 24 | LOCF |
Weeks | Weeks | Weeks | |||||||||||||||||||||||||||||
Hepcidin (ng/mL) | Serum iron ( | μ | Monthly dose of iron, intravenous (mg) | ||||||||||||||||||||||||||||
100 | 100 | g/dL) | 150 | ||||||||||||||||||||||||||||
80 | 90 | 120 | |||||||||||||||||||||||||||||
** | |||||||||||||||||||||||||||||||
60 | * | 80 | 90 | ||||||||||||||||||||||||||||
40 | 70 | 60 | * | ||||||||||||||||||||||||||||
* | |||||||||||||||||||||||||||||||
20 | 60 | 30 | |||||||||||||||||||||||||||||
0 | 50 | 0 | Scr. | BL-2 | 2-4 | 4-6 | 6-8 | 8-1010-12 | 12-16 | 16-20 | 20-24 | ||||||||||||||||||||
BL | 2 | 4 | 6 | 8 | 10 | 12 | 16 | 20 | 24 | LOCF | BL | 2 | 4 | 6 | 8 | 10 | 12 | 16 | 20 | 24 | LOCF | ||||||||||
Weeks | Weeks | Weeks | |||||||||||||||||||||||||||||
VDT | DA |
All data are mean (95% CI). | 14 |
Paired t-test compared with BL for all parameters except monthly dose of iron, which is compared with the screening period: *p<0.01; **p<0.001. |
BL, baseline; LOCF, last observation carried forward; Scr., screening; TIBC, total iron-binding capacity.
Safety Results, 52 Weeks (SAF)
Overview, n (%) | VDT (N = 162) | DA (N = 161) | ||||
Subjects with ≥1 AE | 154 (95.1) | 158 (98.1) | ||||
Adverse drug reaction | 18 (11.1) | 6 | (3.7) | |||
Serious AEs | 41 | (25.3) | 44 | (27.3) | ||
Serious adverse drug reaction | 0 | (0.0) | 0 | (0.0) | ||
Discontinuation due to AEs | 16 (9.9) | 14 (8.7) | ||||
Dose reduction or interruption of study drug due to AEs | 13 (8.0) | 4 | (2.5) | |||
Deaths due to AEs | 2 | (1.2) | 1 | (0.6) | ||
Most common AEs with VDT, n (%) | VDT (N = 162) | DA (N = 161) | ||||
Nasopharyngitis | 74 | (45.7) | 73 | (45.3) | ||
Diarrhea | 25 | (15.4) | 24 | (14.9) | ||
Shunt stenosis | 23 | (14.2) | 26 | (16.1) | ||
AEs of special interest, n (%) | VDT (N = 162) | DA (N = 161) | ||||
Cardiovascular event, cardiac failure | 13 (8.0) | 15 (9.3) | ||||
Retinal disorder | 21 (13.0) | 16 (9.9) | ||||
Malignancy | 7 | (4.3) | 9 | (5.6) | ||
Hyperkalemia | 1 | (0.6) | 1 | (0.6) | ||
Pulmonary hypertension | 0 | (0.0) | 0 | (0.0) | ||
AE, adverse event.
15
Conclusions
- This study demonstrated noninferiority of VDT to DA
- Mean Hb levels in the VDT group were maintained within the target range throughout the 52-week treatment period. Durability of efficacy was confirmed up to week 52
- VDT significantly decreased hepcidin from baseline to week 24, suggesting an improvement in iron metabolism
- Overall, no new safety concerns were identified
- In this study, no meaningful imbalance between groups was observed in the proportion of patients who reported AEs of special interest; however, the AEs of special interest (cardiovascular event, cardiac failure, retinal disorder, malignancy, hyperkalemia, pulmonary hypertension) need to be further investigated across the HIF-PHI class
- These findings support the usefulness of VDT for treating anemia in Japanese patients with CKD on hemodialysis who convert from ESA therapy
16
Attachments
- Original document
- Permalink
Disclaimer
Akebia Therapeutics Inc. published this content on 25 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 July 2020 11:55:12 UTC